OP
VNDA icon

ORG Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

ORG Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,923
Closed -$10.7K – 1380
2024
Q2 		$10.7K Buy
+1,923
New +$9.93K ﹤0.01% 1228

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORG Partners's VNDA Position: Q3 2024 in Review

ORG Partners sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 1,923 shares — an estimated $10.7K sold.

ORG Partners first reported a position in VNDA in Q2 2024 and held it in 1 quarter. The position peaked at $10.7K in Q2 2024. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

  • ORG Partners reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • ORG Partners sold 1,923 Vanda Pharmaceuticals shares in Q3 2024, an estimated $10.7K.
  • ORG Partners first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • ORG Partners's Vanda Pharmaceuticals position peaked at $10.7K in Q2 2024.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.